Q&A

Now & Next: Mavupharma

Source: Jubilant Biosys

Saurabh Kapure,  Vice President, Business  Development,  USA  for  Jubilant Biosys, recently sat down with Michael Gallatin, Ph.D. president and co-founder of Mavupharma (Mavu), the drug discovery and development company, to discuss some of the latest developments in the industry and at Mavu. They chatted for about an hour. During that time, Dr. Gallatin shared his thoughts about Mavupharma, his role at the company, the evolution of biopharma, drug discovery, development, and the road ahead for the industry with Saurabh. The following Q&A, which has been lightly edited for clarity and length, are some key excerpts from their conversation.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development